Abstract
The market for innovative drugs is characterised by a high level of regulation, whose impact on the market is not neutral. Strict regulation may in fact adversely affect incentives to develop new and better products; on the other hand high prices may drive an unsustainable increase of healthcare cost. This trade off is particularly important in Europe where about 75% of drugs cost are financed by the public sector. Uncertainty in the listing process as well as other forms of price regulation may lead to a fairer division of the social value between patents and the industry, but at the cost of leaving some of the potential value of the drug unexploited. In this article we show the impact of different pricing rules on the price and the availability of new drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.